{{Infobox company
| name             = Alkermes plc
| logo             =
| type             = [[Public company|Public]] {{NASDAQ|ALKS}}
| genre            =
| foundation       =
| founder          =
| location_city    = [[Dublin]]
| location_country = [[Ireland]]<ref name=abc>{{cite web |url=http://articles.boston.com/2011-05-10/business/29528836_1_risperdal-consta-richard-pops-ireland |title=Alkermes to buy Irish drug maker |author=Robert Weisman |publisher=''Boston Globe'' |date=10 May 2011 |accessdate=13 October 2011}}</ref>
| location         =
| locations        =
| area_served      =
| key_people       = Richard Pops, CEO
| industry         = [[Biotechnology]]
| products         =
| services         =
| revenue = {{profit}} [[United States Dollar|US$]]187 Million<ref>{{cite web |url=http://www.wikinvest.com/stock/Alkermes_(ALKS)/Data/Income_Statement |title=Alkermes (ALKS) Quarterly Report |date=2011 |publisher=WikiInvest |accessdate=13 October 2011}}</ref>
| operating_income = {{loss}} [[United States Dollar|US$]]-42.9 Million
| net_income     = {{loss}} [[United States Dollar|US$]]-39.6 Million
| assets     = {{decrease}} [[United States dollar|US$]]452 Million
 | equity     = {{decrease}} [[United States dollar|US$]]392 Million
| owner            =
| num_employees    = 1200
| parent           =
| divisions        =
| subsid           =
| homepage         = [http://www.alkermes.com www.alkermes.com]
| footnotes        =
| intl             =
}}
'''Alkermes plc''' is a biopharmaceutical company that focuses on [[central nervous system]] (CNS) diseases. The company is the result of a merger in September 2011 between Alkermes, Inc., and Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of [[Elan Corporation|Élan Corporation, plc]].<ref>{{cite web |url=https://www.forbes.com/2011/05/09/alkermes-to-merge-with-elan-drug-technologies-marketnewsvideo.html |title=Alkermes Reels In Elan's Drug Technology Business |publisher=''Forbes.com'' |date=9 May 2011 |accessdate=13 October 2011}}</ref> The company is headquartered in [[Dublin]], and has an R&D center in [[Waltham, Massachusetts]], and manufacturing facilities in [[Athlone]], [[Ireland]], and [[Wilmington, Ohio]].<ref name=abc />

== Products==
Alkermes has more than 20 commercial drug products and candidates that address serious and chronic diseases, such as addiction, schizophrenia, diabetes and depression. Among these products, five are primary to the company: [[risperidone]] long-acting Injection (generic for ''Risperdal Consta'') for schizophrenia and bipolar 1 disorder,<ref>Zacks Equity Research, “[http://xsltm14.finance.sp2.yahoo.com/news/Positive-Data-on-Risperdal-zacks-520530902.html?x=0 Positive Data on Risperdal Consta],” Yahoo! Finance, March 29, 2011.</ref><ref>John M. Grohol, “[http://psychcentral.com/news/2009/05/18/risperdal-consta-approved-for-bipolar/5974.html Risperdal Consta Approved for Bipolar],” PsychCentral.com, May 18, 2009.</ref> [[paliperidone palmitate]] (generic for ''Invega Sustenna'' in the U.S., ''Xeplion'' in Europe) for schizophrenia,<ref>Cole Petrochko, “[http://www.medpagetoday.com/ProductAlert/Prescriptions/15391 FDA Okays First Monthly Antipsychotic Drug],” MedPage Today, August 5, 2009.</ref><ref>Matt Jarzemsky, “[https://www.wsj.com/article/BT-CO-20110309-707995.html Johnson & Johnson Gets European Approval For Schizophrenia Shot],” ''The Wall Street Journal'', March 9, 2011.</ref> [[4-aminopyridine]] (generic for ''Ampyra'' in the U.S., ''Fampyra'' in Europe) to improve walking in patients with multiple sclerosis,<ref>Susan Jeffrey, “[https://login.medscape.com/login/sso/getlogin?urlCache=aHR0cDovL3d3dy5tZWRzY2FwZS5jb20vdmlld2FydGljbGUvNzE1NzIy&ac=401 FDA Approves Dalfampridine to Improve Walking in Multiple Sclerosis],” Medscape Medical News, January 22, 2010.</ref><ref>Toni Clarke, “[https://www.reuters.com/article/2011/05/20/acorda-biogen-europe-idUSLDE74J0BR20110520 Europe backs Acorda, Biogen drug in change of tack],” Reuters, May 20, 2011.</ref> [[naltrexone]] for extended-release injectable suspension (generic for ''Vivitrol'') for alcohol and opioid dependence,<ref>Miranda Hitti, “[http://www.foxnews.com/story/0,2933,191857,00.html FDA OKs New Drug to Treat Alcoholism],” WebMD, April 14, 2006.</ref><ref>Rita Rubin, “[https://www.usatoday.com/yourlife/health/2010-10-14-opioid14_ST_N.htm FDA OKs Vivitrol to treat heroin, narcotic addictions],” ''USA Today'', October 13, 2010.</ref> and [[exenatide]] extended-release for injectable suspension (generic for ''Bydureon'') for the treatment of type 2 diabetes. ''Bydureon'' is a once-weekly, extended-release form of the drug, exenatide (''Byetta''), and was developed through a partnership between [[Amylin Pharmaceuticals]], Alkermes and [[Eli Lilly and Company|Eli Lilly]]. It is approved in Europe and the U.S.<ref>Denise Mann, "[http://diabetes.webmd.com/news/20120127/weekly-shot-gets-fda-nod-type-2-diabetes Weekly Shot Gets FDA Nod for Type 2 Diabetes]," WebMD, January 27, 2012</ref>

[[Buprenorphine/samidorphan]] (ALKS-5461), a [[κ-opioid receptor]] [[receptor antagonist|antagonist]], is a next-generation, novel [[antidepressant]] which is under development by Alkermes for [[treatment-resistant depression]].<ref name="Harrison2013">{{cite journal|last1=Harrison|first1=Charlotte|title=Trial watch: Opioid receptor blocker shows promise in Phase II depression trial|journal=Nature Reviews Drug Discovery|volume=12|issue=6|year=2013|pages=415–415|issn=1474-1776|doi=10.1038/nrd4028|pmid=23722336}}</ref>

[[Olanzapine/samidorphan]] (ALKS-3831) is an [[atypical antipsychotic]] and [[opioid modulator]] combination that is under development for the treatment of [[schizophrenia]] and [[bipolar disorder|bipolar]] [[mania]].<ref name="pmid27633376">{{cite journal | vauthors = Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C | title = Improving Current Treatments for Schizophrenia | journal = Drug Dev. Res. | volume = 77 | issue = 7 | pages = 357–367 | year = 2016 | pmid = 27633376 | doi = 10.1002/ddr.21337 | url = }}</ref><ref name="pmid28163559">{{cite journal | vauthors = Fellner C | title = New Schizophrenia Treatments Address Unmet Clinical Needs | journal = P T | volume = 42 | issue = 2 | pages = 130–134 | year = 2017 | pmid = 28163559 | pmc = 5265239 | doi = | url = }}</ref>

==References==
{{Reflist|2}}

{{Pharmaceutical companies of the United States}}

{{DEFAULTSORT:Alkermes}}

[[Category:Pharmaceutical companies of Ireland]]
[[Category:Companies based in Dublin (city)]]
[[Category:Companies listed on NASDAQ]]
[[Category:Life sciences industry]]